News

Filter

Unigene and Nordic Bioscience amend JDV accord; Amgen Vectibix China deal

10-05-2013

USA-based Unigene Laboratories (PINK: UGNE) has entered into an equity transfer and exclusive license…

AmgenAnti-Arthritics/RheumaticsBiotechnologyDiabetesLicensingMergers & AcquisitionsNordic BioscienceOncologyPharmaceuticalUGP302Unigene LabsVectibixZhejiang Beta Pharma

Regulatory briefs on Bayer's Stivarga, Boehringer/Lilly's empagliflozin and Pfizer's Xeljanz

26-03-2013

Drug regulator Health Canada has approved German drug major Bayer's Stivarga (regorafenib tablets), indicated…

Anti-Arthritics/RheumaticsAsia-PacificBayerBiotechnologyBoehringer IngelheimDiabetesEli LillyempagliflozinNorth AmericaOncologyPfizerPharmaceuticalRegulationStivargaXeljanz

EMA advisory backs Humira for UC and expanded use of Byetta

20-02-2012

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on Friday…

Abbott LaboratoriesAmylinAnti-Arthritics/RheumaticsBiotechnologyByettaDiabetesEli LillyEuropeGastro-intestinalsHumiraPharmaceuticalRegulation

Targacept licenses nicotine receptor from Cornerstone for up to $75 million

04-08-2010

US firm Targacept has acquired worldwide rights to fellow USA-based Cornerstone Therapeutics’ nicotinic-receptor…

Anti-Arthritics/RheumaticsDiabetesLicensingPharmaceuticalRespiratory and PulmonaryTargacept

Side effects explained: Why common drugs can lead to broken bones

10-06-2010

New research helps to explain why some commonly used drugs come with a serious downside: They up your…

Anti-Arthritics/RheumaticsDiabetesglucocorticoidPharmaceuticalResearchrosiglitazone

Lilly gains global rights to Incyte's novel JAK1/JAK2 inhibitor for $90 million upfront and up to $665 million more; deal with PDL

22-12-2009

US firm Incyte saw its shares rise 5% to $8.92 after announcing it had entered into an exclusive worldwide…

Anti-Arthritics/RheumaticsDiabetesImmunologicalsLicensingLillyNystatinOralPharmaceutical

Back to top